stockrow
Friday 6 November 2026
Export RLYB’s income statement to Excel — free account
Rallybio Corporation
RLYB Healthcare Biotechnology
Rallybio Corporation’s revenue for fiscal 2025 (year ended December 2025) was $858,000.00, up 34.9% from fiscal 2024.
- Revenue
- 0.00%
- EPS
- −116.6%
- Free cash flow
- +65.3%
Quarter to September 2026, against a year earlier
15.74
0.16
−1.01%
Follow RLYB
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | 59.48 | 36.02 | |
P/FCF ratio |
— | — | 0.00 | 0.00 | |
P/Operating CF |
— | — | (6.40) | (6.61) | |
P/B ratio |
— | — | 1.02 | 0.53 | |
Price to Tangible BV |
— | — | 1.02 | 0.53 | |
EV/Sales |
— | — | 4.94 | (27.77) | |
EV/EBITDA |
— | — | 0.00 | 0.71 | |
EV/Operating CF |
— | — | (0.15) | 0.80 | |
EV/FCF |
— | — | (0.15) | 0.80 | |
Quick Ratio |
27.63 | 26.03 | 11.30 | 12.96 | |
Current Ratio |
28.87 | 27.26 | 12.92 | 14.50 | |
Net Debt/EBITDA |
26.50 | 16.42 | 5.33 | 8.41 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.02 | 0.01 | |
Operating CF/Net income |
0.84 | 1.05 | 0.96 | 0.80 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,354.25% | 1,646.40% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 2,865.09% | 1,341.89% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 289.15% | 348.65% | |
Graham Net Nets |
— | — | 0.97 | 1.84 | |
Graham Number |
— | — | 0.00 | 0.00 | |
Earnings Yield |
— | — | (15.18%) | (28.80%) | |
Free Cash Flow Yield |
— | — | (54.12%) | (96.55%) | |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.04 | |
Operating CF per Share |
(0.40) | 8.06 | (1.40) | (0.83) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.40) | 8.06 | (1.40) | (0.83) | |
Cash per Share |
15.87 | 16.29 | 8.23 | 9.72 | |
Shareholders Equity per Share |
16.15 | 16.58 | 8.84 | 10.29 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
16.15 | 16.58 | 8.84 | 10.29 | |
Free Cash Flow |
(2.28) | 45.92 | (7.98) | (4.68) | |
Working Capital |
91.49 | 93.69 | 49.35 | 57.03 | |
Net Current Asset Value |
91.49 | 93.69 | 49.30 | 56.95 | |
EV/EBIT |
— | — | 0.00 | 0.72 | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
Price to Operating Income |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
0.14 | 0.48 | 0.67 | 0.20 | |
Average Assets |
81.62 | 74.53 | 56.23 | 65.18 | |
Average Common Equity |
77.67 | 70.23 | 52.18 | 59.81 |
Columns are period end dates · fundamentals updated 2 Nov 2026